# Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

> **NCT05174013** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** GSK3858279
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05174013
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-14
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-04-17
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174013, "Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05174013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*